A new tool from the lab of Velia Therapeutics co-founder Alan Saghatelian, Ph.D., has proven capable of scouring genetic data for tiny proteins that may serve as new therapeutic targets, opening the ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...